Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)

NCT04129164 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04129164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04129164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
December 9, 2019
Completion date
March 10, 2023
Enrollment
183 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

sjögren's syndrome